FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 5
Volume 15
Issue 5

FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib

FRAZER, Pennsylvania—The FDA has granted orphan drug status to Cephalon, Inc.'s lestaurtinib (CEP-701) for acute myeloid leukemia (AML). The oral compound inhibits several tyrosine kinases including FLT-3 and TrkA. It is in phase II/III trials for AML patients at first relapse who have a FLT-3 activating mutation.

Recent Videos
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
2 KOLs are featured in this series.
Related Content